Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations.

[1]  L. Grohskopf,et al.  Surveillance of Vaccination Coverage Among Adult Populations —United States, 2018 , 2021, Morbidity and mortality weekly report. Surveillance summaries.

[2]  Miwako Kobayashi,et al.  Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices , 2019, MMWR. Morbidity and mortality weekly report.

[3]  Almea M Matanock.  Considerations for PCV13 use among adults ≥65 years old and a summary of the evidence to recommendations framework , 2019 .

[4]  Kenneth J. Smith,et al.  Racial Disparities in Adult Pneumococcal Vaccination Indications and Pneumococcal Hospitalizations in the U.S. , 2019, Journal of the National Medical Association.

[5]  Kenneth J. Smith,et al.  Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general population. , 2019, Vaccine.

[6]  T. Pilishvili.  13-valent pneumococcal conjugate vaccine (PCV13) effects on disease caused by serotype 3 , 2019 .

[7]  A. Leidner.  Overview of three economic analyses of pneumococcal vaccinations at age 65 , 2019 .

[8]  C. Stoecker.  Economic analysis of sustaining the current recommendation for PCV13 use among adults 65 years or older in the context of continued indirect effects from the pediatric PCV13 program , 2018 .

[9]  T. Pilishvili.  Impact of PCV13 on invasive pneumococcal disease (IPD) burden and the serotype distribution in the U.S. , 2018 .

[10]  Eun Ji Kim,et al.  Racial and Ethnic Disparities in Diagnosis of Chronic Medical Conditions in the USA , 2018, Journal of General Internal Medicine.

[11]  H. D. de Melker,et al.  Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands , 2018, PloS one.

[12]  William A. Mattingly,et al.  Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Noele P. Nelson,et al.  Surveillance of Vaccination Coverage among Adult Populations — United States, 2015 , 2017, Morbidity and mortality weekly report. Surveillance summaries.

[14]  M. Bonten,et al.  The impact of community-acquired pneumonia on the health-related quality-of-life in elderly , 2017, BMC Infectious Diseases.

[15]  W. Schaffner,et al.  Socioeconomic Factors Explain Racial Disparities in Invasive Community-Associated Methicillin-Resistant Staphylococcus aureus Disease Rates , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  R. Harpaz,et al.  Prevalence of Immunosuppression Among US Adults, 2013. , 2016, JAMA.

[17]  L. Kim,et al.  Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States , 2016, Journal of General Internal Medicine.

[18]  E. Miller,et al.  Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England , 2016, PloS one.

[19]  Noele P. Nelson,et al.  Surveillance of Vaccination Coverage Among Adult Populations - United States, 2014. , 2016, Morbidity and mortality weekly report. Surveillance summaries.

[20]  W. Self,et al.  Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. , 2015, The New England journal of medicine.

[21]  D. Grobbee,et al.  Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. , 2015, The New England journal of medicine.

[22]  W. Schaffner,et al.  Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. , 2015, The Lancet. Infectious diseases.

[23]  C. Whitney,et al.  Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2014, MMWR. Morbidity and mortality weekly report.

[24]  Joshua T. Cohen,et al.  Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. , 2014, The New England journal of medicine.

[25]  K. O'Brien,et al.  Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic Techniques , 2013, PloS one.

[26]  D. Musher.  Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults? , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  J. Grabenstein.  Effectiveness and serotype coverage: key criteria for pneumococcal vaccines for adults. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  Kenneth J. Smith,et al.  Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. , 2012, JAMA.

[29]  D. Wagener,et al.  Prevalence of high-risk indications for influenza vaccine varies by age, race, and income. , 2010, Vaccine.

[30]  W. Schaffner,et al.  Socioeconomic and racial/ethnic disparities in the incidence of bacteremic pneumonia among US adults. , 2010, American journal of public health.

[31]  W. Anderson,et al.  State-Level Health Care Expenditures Associated With Disability , 2010, Public health reports.

[32]  Kenneth J. Smith,et al.  Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. , 2008, Vaccine.

[33]  C. Whitney,et al.  The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. , 2005, The Journal of infectious diseases.

[34]  C. Whitney,et al.  Cost-Effectiveness of Vaccination against Invasive Pneumococcal Disease among People 50 through 64 Years of Age: Role of Comorbid Conditions and Race , 2003, Annals of Internal Medicine.

[35]  A. Schuchat,et al.  Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. , 2002, Vaccine.

[36]  R. Thompson,et al.  Safety of revaccination with pneumococcal polysaccharide vaccine. , 1999, JAMA.

[37]  D. Fryback,et al.  Toward consistency in cost-utility analyses: using national measures to create condition-specific values. , 1998, Medical care.